Press time:2016-10-28From:CR Pharma [Font:BigMediumSmall]
(28 October, 2016 - Hong Kong) China Resources Pharmaceutical Group Limited ("CR Pharma" or the "Company" , Stock Code: 3320) commenced dealings on the Main Board of the Hong Kong Stock Exchange today.
Mr. Fu Yuning, the Chairman of the China Resources Group and the Chairman of the Board of CR Pharma, stated "Listing on the Main Board of the Stock Exchange of Hong Kong Limited is an important milestone in the history of CR Pharma. CR Pharma listed in Hong Kong would provide a strong capital power to the future development of the company, and open up a wider development space. CR Pharma would take this opportunity to work and focus on being a leading pharmaceutical company in China."
In the morning, a brief and solemn ceremony was held in the Hong Kong Stock Exchange Trading Floor. At 9:30 am, in all the guests to witness and congratulations, Mr. Fu Yuning and Mr,Wang Chuncheng, the Executive Director, Chief Executive Officer and President of the CR Pharma, rang the Opening Bell together.
Mr. Wang Chuncheng stated that after the ceremony "As being the leading company in China pharmaceutical industry, there are lots of opportunities for the company to raise in the future. We are looking for the opportunities of merger actively."
In the evening, CR Pharma held a listing celebration dinner in Hong Kong. Mr.Luo Xi, the General Manager of China Resources Group, conveyed deep appreciation for attentions and supports from all sectors of society on behalf of China Resources Group during the celebration dinner. He said "CR Pharma’s successful listing is part of China Resource Group strategy structure. It affects the effectiveness of medical resources integration and benign interaction of China Resource Group, and also reflects the great social public expectation for the future development of the company. I believe CR Pharma will take this opportunity to consistently bring our customers high-quality products and advanced services, and make a greater contribution to China pharmaceutical industry."
CR Pharma was established in 2007, and has become the second largest pharmaceutical group in mainland China within nine years. The initial public offering of CR Pharma has generated tremendous responses among investors at home and abroad. The Global Offering is initially of a total 1,543,000,000 shares. The net proceeds of the Global Offering are approximately HK$13.67 billion which will be mainly used for strategy acquisition, enhancement of logistics centers, enhancement of research and development platform, enhancement of technology system capabilities of the company and etc.
